Whalesbook
Kerala Ayurveda Ltd (KAL) Q3 FY26 Update: Revenue Climbs Amidst Margin Pressure and Strategic Moves
Kerala Ayurveda Ltd (KAL) has reported a solid top-line performance for the nine months ending December 2025 (YTD Dec'25), with consolidated revenues surging 20.7% year-on-year to Rs. 108.7 Crores. This growth was propelled by strong contributions from the Global E-Product business, which saw a 28% rise YTD and 20% in Q3, and the Global Health Services segment, up 27% YTD and 32% in Q3. India Ecomm also demonstrated robust expansion with 40% growth YTD.
📉 The Financial Deep Dive
Despite the impressive revenue trajectory, profitability metrics indicate pressure points. Adjusted EBITDA for YTD Dec'25 stood at Rs. 6.3 Crores, a marginal increase of Rs. 6 Lakhs compared to the previous year, even with substantial investments in digital marketing, technology, and talent. However, the reported EBITDA margin experienced a significant contraction, falling to Rs. 1.7 Crores from Rs. 6.2 Crores in the prior year period for Q3 YTD Dec'25. This compression, coupled with higher interest expenses and depreciation, resulted in a Profit Before Tax (PBT) of Rs. -8.4 Crores. The company has implemented product price increases after a two-year hiatus to bolster gross margins.
The specific details regarding the balance sheet, cash flow statements, and key financial ratios like ROE/ROCE were not detailed in the provided update. However, the negative PBT and the noted margin contraction are critical areas for investor scrutiny.
Corporate Actions & Strategic Recalibrations
KAL is undertaking significant corporate actions aimed at financial restructuring and consolidation. The promoter group plans to convert Rs. 20 Crores of existing debt into equity through a preferential issue at Rs. 327.99 per share, a ~32% premium to the previous day's closing price. Furthermore, the company intends to acquire the remaining 26% equity stake in its subsidiary, Ayurvedagram Heritage Wellness Centre Private Ltd. (AHWCPL), for Rs. 10 Crores via a preferential issue of KAL shares. This move aims to make AHWCPL a wholly-owned subsidiary, potentially unlocking future merger benefits and tax efficiencies. Strategic recalibrations also include exiting the non-strategic Nutraceutical business (Nutraveda) and reducing US E-commerce marketing spend.
🚩 Risks & Outlook
Management is optimistic about delivering Rs. 150 Crores in consolidated revenue for FY'26, a 23% growth, and is charting an ambitious 'Vision 2030' to scale revenues to Rs. 1000 Crores by the decade's end. Key growth drivers will be continued investments in talent, technology, and international expansion. However, the company acknowledges several risks, including potential delays in fundraising and working capital support, supply chain challenges impacting specific business lines (US E-commerce, India Medical Sales), and potential delays in expansion projects like HS Resorts. The negative PBT remains a concern, though attributed to strategic investments.